<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
      <journal-id journal-id-type="publisher-id">hmg</journal-id>
      <journal-id journal-id-type="hwp">hmg</journal-id>
      <journal-title-group>
        <journal-title>Human Molecular Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0964-6906</issn>
      <issn pub-type="epub">1460-2083</issn>
      <publisher>
        <publisher-name>Oxford University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23842455</article-id>
      <article-id pub-id-type="pmc">3888133</article-id>
      <article-id pub-id-type="doi">10.1093/hmg/ddt312</article-id>
      <article-id pub-id-type="publisher-id">ddt312</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mutations in <italic>STT3A</italic> and <italic>STT3B</italic> cause two congenital disorders of glycosylation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shrimal</surname>
            <given-names>Shiteshu</given-names>
          </name>
          <xref ref-type="aff" rid="af1">1</xref>
          <xref ref-type="author-notes" rid="AN1">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>Bobby G.</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
          <xref ref-type="author-notes" rid="AN1">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Losfeld</surname>
            <given-names>Marie-Estelle</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gilmore</surname>
            <given-names>Reid</given-names>
          </name>
          <xref ref-type="aff" rid="af1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freeze</surname>
            <given-names>Hudson H.</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1"><label>1</label><addr-line>Department of Biochemistry and Molecular Pharmacology</addr-line>, <institution>University of Massachusetts Medical School</institution>, <addr-line>Worcester, MA 01605</addr-line>, <country>USA</country></aff>
      <aff id="af2"><label>2</label><addr-line>Genetic Disease Program</addr-line>, <institution>Sanford Burnham Medical Research Institute</institution>, <addr-line>La Jolla, CA 92037</addr-line>, <country>USA</country></aff>
      <author-notes>
        <corresp id="cor1"><label>*</label>To whom correspondence should be addressed. Tel: +<phone>1 8586463142</phone>; Fax: +<fax>1 8587136281</fax>; Email: <email>hudson@sanfordburnham.org</email></corresp>
        <fn id="AN1">
          <label>&#x2020;</label>
          <p>These authors contributed equally to this study.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <volume>22</volume>
      <issue>22</issue>
      <fpage>4638</fpage>
      <lpage>4645</lpage>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>7</day>
          <month>6</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>6</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
        <copyright-year>2013</copyright-year>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="ddt312.pdf"/>
      <abstract>
        <p>We describe two unreported types of congenital disorders of glycosylation (CDG) which are caused by mutations in different isoforms of the catalytic subunit of the oligosaccharyltransferase (OST). Each isoform is encoded by a different gene (STT3A or STT3B), resides in a different OST complex and has distinct donor and acceptor substrate specificities with partially overlapping functions in N-glycosylation. The two cases from unrelated consanguineous families both show neurologic abnormalities, hypotonia, intellectual disability, failure to thrive and feeding problems. A homozygous mutation (c.1877T &gt; C) in <italic>STT3A</italic> causes a p.Val626Ala change and a homozygous intronic mutation (c.1539 + 20G &gt; T) in <italic>STT3B</italic> causes the other disorder. Both mutations impair glycosylation of a GFP biomarker and are rescued with the corresponding cDNA. Glycosylation of STT3A- and STT3B-specific acceptors is decreased in fibroblasts carrying the corresponding mutated gene and expression of the STT3A (p.Val626Ala) allele in STT3A-deficient HeLa cells does not rescue glycosylation. No additional cases were found in our collection or in reviewing various databases. The <italic>STT3A</italic> mutation significantly impairs glycosylation of the biomarker transferrin, but the <italic>STT3B</italic> mutation only slightly affects its glycosylation. Additional cases of STT3B-CDG may be missed by transferrin analysis and will require exome or genome sequencing.</p>
      </abstract>
    </article-meta>
  </front>
</article>
</pmc-articleset>